Francesco Sergio works in the pharmaceutical industry from January 2004 to May 2018. Knowledge of Drug Development, in Global Medical Affairs leading Respiratory area (COPD, Asthma, Bronchiectasis, Cystic Fibrosis) and experience in Regulatory Submissions (e.g. EMA, Chinese SFDA, BfArM, ANVISA, AIFA, MEB). In Philip Morris International leading the Respiratory Area in the R&D group.
He got his Degree in Medicine at the University of Parma, Faculty of Medicine and Surgery, and Postgraduate degree in Respiratory Diseases, at the University of Parma, Faculty of Medicine and Surgery – Post graduate School in Respiratory Diseases (Vote: 50/50 cum laude).
Since June 2018 he is Medical Director, Science and Innovation – Clinical Science and Epidemiology at Philip Morris International – Neuchatel, Switzerland.
In the Respiratory Area (COPD, asthma) he is accountable for defining the assessment strategy to assess the Disease Risk Reduction potential of PMI RRPs. As senior medical liaison and mentor he interacts with Senior Management, Executive Steering Committee and R&D Steering Committee, Corporate and Regulatory Affairs, Communications and Legal, relevant internal and external stakeholders as well as public health professionals and health care organizations, disease advocacy groups and societies as well as worldwide KOLs in order to understand the latest business issues, assessment strategies and methodologies, gain support and adapt the scientific assessment and medical communication strategies accordingly. He ensures scientific soundness of the proposed assessment program and secures PMI success in this strategic area enabling the PMI vision of a smoke free world and full transition of PMI to an RRP company; formulates publications plans, prepares the reporting of pivotal clinical study results to relevant authorities and present such results at scientific meetings and through journal articles. In close collaboration with Regulatory Affairs, Corporate Affairs and the Legal Department he ensures accurateness of all written documents provided to relevant authorities from a medical perspective and include the necessary content mandated in the respective guidelines. He supports the product surveillance organization, reviewing individual severe adverse event reports, and safety signals as well as internal and external evaluation and communication related to safety aspects of RRPs ensuring the communication medically sound and accurate.Share articles :